OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review
Liang‐Fang Wang, Pingrun Chen, Si-Ke He, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 29, pp. 4481-4498
Open Access | Times Cited: 12
Liang‐Fang Wang, Pingrun Chen, Si-Ke He, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 29, pp. 4481-4498
Open Access | Times Cited: 12
Showing 12 citing articles:
Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis
Yue Yang, Kan-Zuo Fu, Pan Gu
World Journal of Gastrointestinal Surgery (2024) Vol. 16, Iss. 1, pp. 228-238
Open Access | Times Cited: 7
Yue Yang, Kan-Zuo Fu, Pan Gu
World Journal of Gastrointestinal Surgery (2024) Vol. 16, Iss. 1, pp. 228-238
Open Access | Times Cited: 7
Powerful and accurate case-control analysis of spatial molecular data with deep learning-defined tissue microniches
Yakir Reshef, Lakshay Sood, Michelle Curtis, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Yakir Reshef, Lakshay Sood, Michelle Curtis, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
MK2 Inhibition in CD4+ T Cells Protects Against IFNγ and IL-17A, Chronic Inflammation, and Fibrosis in Inflammatory Bowel Disease Models
Cody Howe, Marina Chulkina, Ryan Syrcle, et al.
Inflammatory Bowel Diseases (2025)
Closed Access
Cody Howe, Marina Chulkina, Ryan Syrcle, et al.
Inflammatory Bowel Diseases (2025)
Closed Access
Association of early therapeutic drug monitoring of adalimumab with biologic remission and drug survival in Crohn’s Disease
J L Rueda García, Cristina Suárez Ferrer, Clara Amiama Roig, et al.
Therapeutic Advances in Gastroenterology (2025) Vol. 18
Open Access
J L Rueda García, Cristina Suárez Ferrer, Clara Amiama Roig, et al.
Therapeutic Advances in Gastroenterology (2025) Vol. 18
Open Access
Predictors of Immunogenicity and Loss of Response to ANTI-TNFα Therapy in Crohn Disease—A Systematic Review
Simona Grad, Radu A. Fărcaș, Dan L. Dumitrașcu, et al.
American Journal of Therapeutics (2025) Vol. 32, Iss. 3, pp. e262-e268
Closed Access
Simona Grad, Radu A. Fărcaș, Dan L. Dumitrașcu, et al.
American Journal of Therapeutics (2025) Vol. 32, Iss. 3, pp. e262-e268
Closed Access
Approach to loss of response to advanced therapies in inflammatory bowel disease
Nikil Vootukuru, Abhinav Vasudevan
World Journal of Gastroenterology (2024) Vol. 30, Iss. 22, pp. 2902-2919
Open Access | Times Cited: 2
Nikil Vootukuru, Abhinav Vasudevan
World Journal of Gastroenterology (2024) Vol. 30, Iss. 22, pp. 2902-2919
Open Access | Times Cited: 2
Efficacy of Second-Line Biological Therapies in Moderate to Severe Ulcerative Colitis Patients with Prior Failure of Anti-Tumor Necrosis Factor Therapy: A Multi-Center Study
Ji-Eun Na, Yong-Eun Park, Jongha Park, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 10, pp. 1066-1066
Open Access | Times Cited: 2
Ji-Eun Na, Yong-Eun Park, Jongha Park, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 10, pp. 1066-1066
Open Access | Times Cited: 2
Clinical use of tumor necrosis factor-alpha inhibitors in Iraq: a review of their documented efficacy, safety, and associated genetics
Ahmad Al-Jalehawi, Samer Imad Mohammed
Review of Clinical Pharmacology and Pharmacokinetics - International Edition (2024) Vol. 38, Iss. 3, pp. 335-346
Open Access | Times Cited: 1
Ahmad Al-Jalehawi, Samer Imad Mohammed
Review of Clinical Pharmacology and Pharmacokinetics - International Edition (2024) Vol. 38, Iss. 3, pp. 335-346
Open Access | Times Cited: 1
Terapia Biológica y Moduladores del Sistema Inmunológico en el tratamiento de las Enfermedades Inflamatorias Intestinales
Evelyn Estefanía Jaramillo Castillo, Danilo Muñoz Palomeque
Salud ConCiencia (2023) Vol. 2, Iss. 2, pp. e32-e32
Open Access | Times Cited: 1
Evelyn Estefanía Jaramillo Castillo, Danilo Muñoz Palomeque
Salud ConCiencia (2023) Vol. 2, Iss. 2, pp. e32-e32
Open Access | Times Cited: 1
Evaluation of adropin, fibroblast growth factor-1 (FGF-1), and Toll-like receptor-1 (TLR1) biomarkers in patients with inflammatory bowel disease: gene expression of TNF-α as a marker of disease severity
Moushira Zaki, Hisham A. Orban, Marwa Mahmoud, et al.
Egyptian Journal of Medical Human Genetics (2024) Vol. 25, Iss. 1
Open Access
Moushira Zaki, Hisham A. Orban, Marwa Mahmoud, et al.
Egyptian Journal of Medical Human Genetics (2024) Vol. 25, Iss. 1
Open Access
Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovations
Shi‐Yan Zhang
World Journal of Gastroenterology (2024) Vol. 30, Iss. 41, pp. 4411-4416
Closed Access
Shi‐Yan Zhang
World Journal of Gastroenterology (2024) Vol. 30, Iss. 41, pp. 4411-4416
Closed Access
Impact Of Hladqa1*05 And Hladqa1*03 On Safety And Loss Of Response To Anti-Tnf In Patients With Inflammatory Bowel Disease
Julia López de la Cruz, Fernando Gomollón, Javier Louro, et al.
Journal of Crohn s and Colitis (2024)
Closed Access
Julia López de la Cruz, Fernando Gomollón, Javier Louro, et al.
Journal of Crohn s and Colitis (2024)
Closed Access
